Protocol Ledger

NCT07227454 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Interventional Phase III clinical trial protocol NCT07227454 sponsored by Johnson & Johnson / Janssen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-08 Enrollment: 258 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07227454
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)258 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07227454
Protocol FieldVerified Registry Value
NCT IdentifierNCT07227454
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment258 participants (ESTIMATED)
Registered Start Date2026-01-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI